High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01613-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Alejandro Armesilla-Diaz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Sciences, GlaxoSmithKline, Stevenage, United Kingdom. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Macrophages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Ministerio de Ciencia, Innovación y Universidades, European Commission.
Abstract (Originalsprache)
New treatments are still necessary to eradicate tuberculosis disease. Macrophages derived from human induced pluripotent stem cells (hiPSC-Macs) offer a physiological niche to identify potential new drugs in the context of Mycobacterium tuberculosis (Mtb) infection. Here, we describe the scale-up of hiPSC-Macs production in 5-stack chambers for high-throughput drug screening against Mtb. A rate of approximately 100 million hiPSC-Macs was generated with optimal quality for a period of up to 12 weeks. Moreover, the infection model was optimized using a luminescence-based Mtb reporter strain. The assay showed enough sensitivity to identify compounds that could target host-pathogen interactions during Mtb infection. We interrogated a library of 200,000 compounds in Mtb-infected hiPSC-Macs with a Z-score above 0.3 in all plates analyzed. After secondary assays, 223 qualified hits were selected for further progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genomics Sciences, GlaxoSmithKline, Stevenage, United Kingdom.
- Global Health Medicines R&D, GlaxoSmithKline, Madrid, Spain.
- MMD-MD, GlaxoSmithKline, Madrid, Spain.
ORCID-Profile: Alejandro Armesilla-Diaz, Eugenia Meiler, Laura Padrón-Barthe
Förderung
- Wellcome Trust
- Ministerio de Ciencia, Innovación y Universidades
- European Commission
Zitieren
APA
Armesilla-Diaz, A., Pilar Arenaz, M., Ashby, C., Blanco, D., D'Oria, E., Garuti, H., Gómez, V., González-Del-Río, R., Martínez-Hoyos, M., Meiler, E., Mendoza-Losana, A., Mohamet, L., Padrón-Barthe, L., Pérez, E., Pérez, L., Remuiñán, M. J., Rodríguez-Miquel, B., Segura-Carro, D., & Viera-Morilla, S. (2025). High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01613-24
Vancouver
Armesilla-Diaz A, Pilar Arenaz M, Ashby C, Blanco D, D'Oria E, Garuti H, et al. High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01613-24
BibTeX
@article{ArmesillaDiaz2025,
author = {Armesilla-Diaz, Alejandro and Pilar Arenaz, María and Ashby, Charlotte and Blanco, Delia and D'Oria, Emiliana and Garuti, Helena and Gómez, Vanesa and González-Del-Río, Rubén and Martínez-Hoyos, María and Meiler, Eugenia and Mendoza-Losana, Alfonso and Mohamet, Lisa and Padrón-Barthe, Laura and Pérez, Esther and Pérez, Laura and Remuiñán, Modesto J and Rodríguez-Miquel, Beatriz and Segura-Carro, Delfina and Viera-Morilla, Sara},
title = {High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01613-24}
}
EUVIMED